Compare Costco Wholesale Corporation (COST) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Mesoblast Limited — how do they compare? Costco Wholesale Corporation trades at $921.77 (market cap $408.78B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Costco Wholesale Corporation is far larger — about 192.8× Mesoblast Limited's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| COST | MESO | |
|---|---|---|
Market Cap | $408.78B | $2.12B |
Sector | Consumer Staples | Technology |
52-Week High | $1.09K | $20.96 |
52-Week Low | $849.63 | $10.96 |
Enterprise Value | $396.92B | $2.13B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $926.43, up 1.11% today, with a bearish technical signal but strong fundamentals. Revenue grew to $275.24B in 2025, with net income up to $8.10B, and March 2026 sales surged 11.3% year-over-year (Costco report, April 8, 2026). Valuation ratios are elevated, with a P/E of 46.6, while analyst consensus is bullish with a $1,120 price target. Recent membership fee hikes and institutional buying support growth prospects.
Outlook remains positive due to steady revenue growth and high membership renewal rates, but risks include rich valuations and competitive pressures. The stock offers long-term value if pullbacks occur, with earnings momentum key for upside. Bearish technicals suggest near-term caution, though fundamentals underpin investor confidence.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
